Novartis Foundation confirms Dr Joerg Reinhard as new chairman
pharmafile | July 27, 2015 | Appointment | Manufacturing and Production, Medical Communications |Â Â Dr Joerg Reinhardt, NovartisÂ
The Novartis Foundation has confirmed several new members of its board of trustees, including a new chairman in Dr Joerg Reinhardt, who is also chairman of the Novartis board of directors.
He will serve as chairman of the foundation’s board of trustees, along with new members Professor Peter Piot of the London School of Hygiene and Tropical Medicine, Dr Rebecca Weintraub of Harvard Medical School, and Rainer Boehm from Novartis Pharmaceuticals.
Juergen Brokatzky-Geiger, global head of corporate responsibility for Novartis, and Dr Ann Aerts, head of the Novartis Foundation, will remain on the board. Previous board members George Gunn and Professor Jean-Marie Lehn have both stepped down in the past year.
“The Novartis Foundation has been committed to improving healthcare for the poorest populations for more than 35 years,” Dr Reinhardt says. “I am happy to contribute to the continuation of this important work and to welcome two external board members who bring a wealth of experience and expertise in global health as well as a fresh perspective on the Novartis Foundation.”
While Professor Piot says: “We are at a crucial point in global health. In low- and middle-income countries we still struggle with managing infectious disease, maternal and child health and malnutrition, while at the same time, there is a growing crisis of non-communicable diseases such as heart disease and diabetes. There is also the emergence of technology and connectivity that allows us to reach patients and healthcare professionals more than ever before.
“I am excited to be part of the Novartis Foundation team working with the global health community to innovate healthcare delivery addressing this double burden of disease to improve the health of people in these geographies and to empower their communities and governments to sustain improved health services for the long term.”
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …
